Pancreatic Cancer Research

Clinical trialPhase 3Completed

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

A Randomized Placebo Controlled Study of OSI-774 (Tarceva (TM)) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

NCT00040183↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Finished, no results posted
Phase
Phase 3
Status
Completed
Study type
Interventional
Start
29 November 2001
Expected end
15 January 2004
Enrollment
569 participants
Sites
140
Sponsor
Industry
Results posted
No
Last update
10 January 2018

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 2